TV News LIES

Tuesday, May 07th

Last update09:41:29 PM GMT

You are here All News At a Glance Health Glance

FDA approves first cell therapy to treat aggressive forms of melanoma

FDA approves cell treatment for some melanomaThe Food and Drug Administration has approved a novel type of cancer therapy to treat aggressive forms of melanoma using immune system cells from a patient's tumor.

The treatment, called Amtagvi, was developed by Iovance Biotherapeutics, a biotech company based in San Carlos, Calif.

It is intended for patients whose melanoma cannot be removed with surgery or has spread to other parts of the body.

"The approval of Amtagvi represents the culmination of scientific and clinical research efforts leading to a novel T cell immunotherapy for patients with limited treatment options," Dr. Peter Marks, the director of the FDA's Center for Biologics Evaluation and Research, said in a statement announcing the approval on Friday.

More...

Research at the heart of a federal case against the abortion pill has been retracted

Mifebrex

A scientific paper that raised concerns about the safety of the abortion pill mifepristone was retracted by its publisher this week. The study was cited three times by a federal judge who ruled against mifepristone last spring. That case, which could limit access to mifepristone throughout the country, will soon be heard in the Supreme Court.

The now retracted study used Medicaid claims data to track E.R. visits by patients in the month after having an abortion. The study found a much higher rate of complications than similar studies that have examined abortion safety.

Read more...

Patients say keto helps with their mental illness. Science is racing to understand why

Ian Campbell, Keto researcher

Iain Campbell was gazing out the bus window on his way to work when he first sensed something radical was reshaping how he experienced the world.

The inkling emerged from an altogether ordinary observation: He felt peaceful, maybe even happy as he watched the trees along the road pass by.

"I hadn't experienced that in a really long time, probably since I was a kid," says Campbell, who lives in Edinburgh, Scotland.

"I didn't know what was going on at the time, but I thought this might be what it feels like to be normal."

More...

Florida Official Raises Alarms About DNA in COVID-19 Vaccines

FL Surgeon General LapadoFlorida Surgeon General Joseph Ladapo is raising alarms about what he sees as the risk of potential cancer posed by COVID vaccines.

Ladapo, who rose to national prominence during the pandemic for spreading misinformation about the virus and promoting vaccination hesitancy, is asking the Food and Drug Administration (FDA) and the U.S. Centers for Disease Control and Prevention (CDC) to answer questions about his concerns regarding DNA integration in mRNA vaccines.

Read more...

FDA approves Zepbound, a new obesity drug that will take on Wegovy

FDA approves Zepbound, new weight loss drug

An obesity drug called Zepbound won approval for use in adults from the Food and Drug Administration Wednesday, ushering in a new rival to Novo Nordisk's blockbuster Wegovy.

Eli Lilly & Co., maker of Zepbound, says it shows greater weight loss at a lower list price than Wegovy. The Lilly drug will be available in the U.S. by the end of the year. A version of the shot, known generically as tirezepatide, is already sold as Mounjaro to treat Type 2 diabetes.

The Lilly drug works by acting on two hormone receptors in the brain, including one called GLP-1, short for glucagon-like peptide-1 – that regulate appetite and metabolism.

The new class of medicines for managing obesity that includes Zepbound and Wegovy has given people with obesity and overweight a potent option for treatment. But the drugs are expensive, and many people who lose weight regain it after stopping the medicines.

More...

US chemical industry likely spent $110m trying to thwart PFAS legislation, study finds

Chem industry spent $110m to stop legislation

The US chemical industry likely spent over $110m during the last two election cycles deploying lobbyists to kill dozens of pieces of PFAS legislation and slow administrative regulation around “forever chemicals”, a new analysis of federal lobbying documents has found.

The industry’s onslaught was effective: only eight pieces of legislation that targeted PFAS made it through Congress, the paper prepared by the Food and Water Watch (FWW) nonprofit found.

“There’s an extreme amount of money that’s going into fighting [PFAS legislation],” said Amanda Starbuck, FWW’s research director and the lead author on the report. “It’s hard to win these fights when there’s so much funding being put in from the opposing side.”

Read more...

Women denied abortions file lawsuits in Idaho, Tennessee and Oklahoma over bans

Women denied abortions sues statesAn abortion rights advocacy group filed lawsuits in three states on Tuesday on behalf of women who say they were denied abortions despite suffering life-threatening pregnancy complications.

The Center for Reproductive Rights sued on behalf of eight women and four doctors in Idaho, Tennessee and Oklahoma, three states that have passed some of the strictest abortion bans since the U.S. Supreme Court gutted federal abortion rights by overturning Roe v. Wade in 2022.

The lawsuits follow a similar case brought by the center in Texas, where a judge last month sided with five women who were denied abortions and exempted women experiencing pregnancy complications from Texas' stringent abortion ban.

The lawsuits in Idaho and Tennessee ask the state courts to clarify those states' legal exceptions for abortions in cases of medical emergencies, so that doctors may perform abortions when they deem them necessary without fear of prosecution.

More...

Page 5 of 231

 
America's # 1 Enemy
Tee Shirt
& Help Support TvNewsLIES.org!
TVNL Tee Shirt
 
TVNL TOTE BAG
Conserve our Planet
& Help Support TvNewsLIES.org!
 
Get your 9/11 & Media
Deception Dollars
& Help Support TvNewsLIES.org!
 
The Loaded Deck
The First & the Best!
The Media & Bush Admin Exposed!